talaporfin and Mouth-Neoplasms

To assess the effect of photodynamic therapy (PDT) with talaporfin sodium, a second-generation photosensitizer, on oral squamous cell carcinoma (SCC).. Eight patients who were diagnosed with oral SCC without any metastasis and underwent talaporfin sodium-mediated PDT (t-PDT) were included in this study. Biopsies were performed 4-6 weeks after t-PDT. The clinical response was evaluated using Response Evaluation Criteria in Solid Tumors.. Complete response (CR) was achieved in six of eight cases, and two cases showed partial response (PR) as a clinical outcome of t-PDT. Recurrence occurred in one of the CR cases 9 months after irradiation. The patient underwent tumor resection and no recurrence was found after surgery. The two cases with PR died from the cancer despite additional PDT.. t-PDT is an effective treatment strategy for oral SCC. Talaporfin sodium has an advantage with regard to early elimination from the body compared with porfimer sodium.

Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Humans; Lasers, Semiconductor; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Photochemotherapy; Photosensitizing Agents; Porphyrins

Talaporfin sodium (Laserphyrin, Meiji Seika, Tokyo, Japan) is a second-generation photosensitizer developed in Japan. It is characterized by both mild and short-term skin photosensitivity. The objective of this study was to evaluate the efficacy and the pharmacokinetic characteristics in tumor tissues in patients with head and neck cancer.. (1) Four hours after administration intravenous injection of talaporfin sodium (40 mg/m(2)), 100mg tissue specimens were taken from the central part of the tumor. The samples were analyzed by reverse phase liquid chromatography and concentrations were measured. (2) Four hours after intravenous injection of talaporfin sodium (40 mg/m(2)), we gave 60-150 J/cm(2) of 664 nm laser irradiation with a diode laser (PD laser, Panasonic, Japan). Biopsies were performed at 4 weeks and at 3 months after treatment and periodically thereafter to confirm the treatment efficacy of photodynamic therapy (PDT).. Of the 14 patients who grope informed consent, more than 1 microg/g of talaporfin sodium was found in the tumor tissues in 13. Moreover, in 9 patients, tumor-to-normal-tissue ratios ranged from 2.32:1 to 5.69:1, which indicates that more than double the amount of talaporfin sodium was maintained within the tumor than in normal tissues. We have enrolled 22 patients with head and neck cancer with no clinically recognizable metastases after obtaining written informed consent to participate in this study. PDT using talaporfin sodium exhibited the equivalent efficacy to that of conventional PDT using hematoporphyrin derivative (HpD).. The results using a combination of talaporfin sodium and PD laser achieved a primary treatment outcome equivalent to that of conventional PDT. This method has also proven to be advantageous because of the reduced incidence of side effects such as photosensitivity and local edema.

Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Injections, Intravenous; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Pharyngeal Neoplasms; Photochemotherapy; Photosensitizing Agents; Porphyrins; Treatment Outcome

Photodynamic therapy (PDT) is a method for treating pre-cancerous and cancerous lesions of the skin, bladder and oral cavity. However, tumour recurrence after PDT remains problematic despite good initial response. Some studies have shown that PDT induces vascular endothelial growth factor (VEGF) expression in human oral squamous cell carcinoma and other organs. However, little is known about VEGF expression applied to PDT in human carcinoma cell lines. No studies have been conducted of PDT using Npe6 (Npe6-mediated PDT), a second-generation photosensitizer, in the human oral carcinoma cell line, HSC-3 cells. We investigated the expression of VEGF, c-jun and c-fos proto-oncogenes in HSC-3 cells in response to Npe6-mediated PDT. We also addressed the possibility that oxidative damage induced by PDT could lead to an angiogenic response, via VEGF expression. Reverse transcription polymerase chain reaction (RT-PCR) analysis revealed that Npe6-mediated PDT induced the expression of mRNAs for VEGF, c-jun and c-fos in time- and concentration-dependent manners. Desferrioxamine (DFX), an iron chelator, induced VEGF expression, but the expression pattern was different to that of Npe6-mediated PDT. The expression mRNAs for VEGF, c-jun and c-fos induced by Npe6-mediated PDT were inhibited by SB203580, p38 MAPK inhibitors, and the expression of VEGF mRNA was inhibited by cycloheximide (CHX), a protein synthesis inhibitor. The c-jun mRNA expression was inhibited, whereas the c-fos mRNA expression was enhanced by N-acetyl-L-cysteine (NAC), a free radical scavenger. We conclude that Npe6-mediated PDT induces the expression of VEGF, c-jun and c-fos in human oral carcinoma cell line, HSC-3 cell, and at least partly, through the activation of p38 MAPK.

Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cycloheximide; Deferoxamine; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Free Radical Scavengers; Genes, fos; Genes, jun; Humans; Imidazoles; Mouth Neoplasms; p38 Mitogen-Activated Protein Kinases; Photochemotherapy; Photosensitizing Agents; Porphyrins; Protein Synthesis Inhibitors; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Siderophores; Vascular Endothelial Growth Factor A